Kane Biotech Inc. (CVE:KNE – Get Free Report)’s share price rose 28.6% during trading on Saturday . The company traded as high as C$0.05 and last traded at C$0.05. Approximately 1,505,028 shares were traded during trading, an increase of 380% from the average daily volume of 313,629 shares. The stock had previously closed at C$0.04.
Kane Biotech Price Performance
The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The stock has a market capitalization of C$7.53 million, a price-to-earnings ratio of -0.56 and a beta of 0.60. The stock has a 50 day moving average price of C$0.04 and a 200-day moving average price of C$0.04.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Articles
- Five stocks we like better than Kane Biotech
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
